PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.…
PAVmed (PAVM) Q3 2026 Earnings Call Transcript
PAVmed (NASDAQ: PAVM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 41 employees.
The shares were at 1.135 USD on 20 November 2026, down 88.0% over 52 weeks. Its 52-week range is 1.100 USD to 28.44 USD: the price is 96.0% below the high and 3.2% above the low.
Its market capitalisation is 9.08M USD.
PAVmed reports return on equity of 1.2% and revenue up 720.0% year over year.
Its debt exceeds its cash by 12.39M USD, a debt-to-equity ratio of 0.39. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 29 March 2027.